A STUDY SHOWING THE EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | ||||
| Al-Azhar Journal of Pharmaceutical Sciences | ||||
| Article 10, Volume 54, Issue 1, March and April 2016, Page 137-147 PDF (680.52 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ajps.2018.6639 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| Zeina Hussein | ||||
| Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Abbasia, Cairo, Egypt | ||||
| Abstract | ||||
| Angiotensin receptor blockers (ARBs) were developed for the treatment of high blood pressure to antagonize increased angiotensin II-dependent vasoconstriction. The aim of our study was to evaluate whether irbesartan had beneficial effects on the reduction of prostate weight in a rat model of benign prostatic hyperplasia (BPH). Benign prostatic hyperplasia was induced by subcutaneous injections of testosterone enanthate for four weeks in albino rats, and rats were treated with or without oral doses of irbesartan (10,20 and 40mg/kg) for five consecutive days per week for four successive weeks during BPH induction. After 4 weeks, the protein abundance of nuclear factor kappa-B was assessed immunohistochemically in the prostate tissue taken from the different treatment groups. The irbesartan (40 mg/kg)-treated group showed a significant decrease in prostate weight, prostate index and nuclear factor kappa-B abundance compared to the non-treated BPH group. These results show that irbesartan is effective in decreasing the weight and proliferation of the prostate, and suggest that irbesartan may be an effective treatment for BPH. | ||||
|
Statistics Article View: 271 PDF Download: 719 |
||||
